The effects of coenzyme q10 supplementation on metabolic profiles of patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials

Bakhshayeshkaram, M. and Lankarani, K.B. and Mirhosseini, N. and Tabrizi, R. and Akbari, M. and Dabbaghmanesh, M.H. and Asemi, Z. (2018) The effects of coenzyme q10 supplementation on metabolic profiles of patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. Current Pharmaceutical Design, 24 (31). pp. 3710-3723.

[img] Text
scopusresults(7).pdf

Download (61kB)
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....
DOI: UNSPECIFIED

Abstract

Background: This systematic review and meta-analysis of Randomized Controlled Trials (RCTs) were conducted to determine the effects of coenzyme Q10 (CoQ10) supplementation on metabolic profiles of patients diagnosed with Chronic Kidney Disease (CKD). Methods: Two independent reviewers systematically searched online databases including PubMed, Cochrane Library, and Web of Science databases, Scopus, EMBASE until July 2018 to identify eligible clinical trials. The heterogeneity across included trials was assessed using Cochran�s Q test and I-square (I 2 ) statistic. Cochrane Collaboration risk of bias tool was applied to evaluate the quality of selected RCTs. Standardized mean difference (SMD) and 95 Confidence Interval (CI) between two groups of intervention were used to determine pooled effect sizes. Results: Out of 721 potential papers, 7 RCTs were appropriate to be included in our meta-analysis. The pooled results revealed that CoQ10 supplementation significantly reduced total-cholesterol (SMD=-0.58; CI,-0.94,-0.21; P=0.002; I 2 : 54.9), LDL-cholesterol (SMD=-0.47; 95 CI,-0.78,-0.17; P=0.003; I 2 :00.0), malondialde-hyde (MDA) (SMD=-3.0; 95 CI,-5.10,-0.90; P=0.005; I 2 : 95.4) and creatinine levels (SMD=-1.65; 95 CI,-2.75,-0.54; P=0.003; I 2 : 95.0) in patients diagnosed with CKD. Triglycerides, HDL-cholesterol, fasting glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and C-reactive protein (CRP) concentrations did not affect following CoQ10 supplementation. Conclusion: Overall, the current meta-analysis demonstrated that CoQ10 supplementation significantly improved metabolic profile in patients with CKD by reducing total cholesterol, LDL-cholesterol, MDA and creatinine levels, yet it did not affect fasting glucose, insulin, HOMA-IR, and CRP concentrations. © 2018, Bentham Science Publishers B.V. All rights reserved.

Item Type: Article
Additional Information: cited By 1
Uncontrolled Keywords: C reactive protein; cholesterol; creatinine; glucose; high density lipoprotein cholesterol; low density lipoprotein cholesterol; malonaldehyde; triacylglycerol; ubidecarenone, cholesterol blood level; chronic kidney failure; clinical effectiveness; diet supplementation; glucose blood level; homeostasis model assessment; human; meta analysis; metabolic parameters; oxidative stress; priority journal; randomized controlled trial (topic); Review; risk assessment; risk factor; systematic review; treatment duration; treatment outcome; treatment response; triacylglycerol blood level
Subjects: Medicine
Health Professions
Divisions: Faculty of Nursing & Midwifery > Department of Management & Health
Depositing User: ART . editor
Date Deposited: 10 Apr 2019 10:58
Last Modified: 10 Apr 2019 10:58
URI: http://eprints.kaums.ac.ir/id/eprint/4073

Actions (login required)

View Item View Item